What's Happening?
Phanes Therapeutics, a clinical-stage biotech company, has announced promising results from its Phase 2 clinical trial of spevatamig (PT886) in combination with chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The results were
presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Spevatamig, a bispecific antibody targeting claudin 18.2 and CD47, showed a 52.4% overall response rate and a 90.5% disease control rate when combined with chemotherapy. The trial involved over 190 patients globally, demonstrating that the combination is well-tolerated with no significant additive toxicity. The median progression-free survival was 7.3 months, and the median overall survival was 14.7 months among U.S. patients. These findings support further development of spevatamig in a Phase 3 trial.
Why It's Important?
The development of spevatamig is significant as it offers a new treatment avenue for metastatic PDAC, a cancer type known for its poor response to existing therapies. The drug's ability to enhance innate immunity by activating macrophages and dendritic cells provides an alternative to traditional immune checkpoint inhibitors, which are less effective against 'cold tumors' like PDAC. This advancement could potentially improve survival rates and quality of life for patients with this aggressive cancer. The FDA's orphan drug and Fast Track designations for spevatamig underscore its potential to address unmet medical needs in oncology, particularly for patients with limited treatment options.
What's Next?
Phanes Therapeutics plans to advance spevatamig to a Phase 3 registrational study, with enrollment at the 3 mg/kg dose level progressing rapidly. The company aims to gather efficacy data by the second half of 2026, potentially leading to a Phase 3 readiness shortly thereafter. This progression could pave the way for spevatamig to become a standard treatment option for metastatic PDAC, pending successful trial outcomes. The collaboration with Merck to study spevatamig in combination with pembrolizumab further highlights the drug's potential in combination therapies.
